All News

It's interesting that we saw such a clear U-shaped mortality curve for serum bicarbonate levels in a patient population where we usually don't think about measuring bicarbonate, said Manan Pareek, MD, PhD, FAHA, FESC, an internal medicine hospital resident at the Yale University School of Medicine.

Having 2 trials that both show benefits of SGLT2 inhibitors in heart failure hospitalizations can only encourage the use of these drugs, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.

Advances in imaging have made assessment of atherosclerosis non-invasive, while the EVAPORATE trial demonstrates how cardiac CT can assist in looking at a host of different therapies, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

Results from the second major renal outcomes trial for an SGLT2 inhibitor affirm the role of the class in preventing renal decline and kidney failure.

The PARALLAX study points to potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction, which has no approved treatments.

Of the top 10% considered high cost from an overall cohort of 21 million, a recent study by Milliman found that 57% of this high-cost group had a mental health or substance abuse diagnosis. This behavioral subgroup was shown to contribute to 44% of all health care spending, said Henry Harbin, MD, leading behavioral health expert and adviser to The Bowman Family Foundation.

It's very important to take the EMPEROR-Reduced and DAPA-HF trials together as being complementary, said Milton Packer, MD, of Baylor University Medical Center in Dallas and University of Texas Southwestern Medical School.

In this most recent analysis of REDUCE-IT, results show a consistent benefit favoring icosapent ethyl versus placebo irrespective of the actual statin type, said Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School.

Patients were more likely to report more relapses of multiple sclerosis than physicians.

Early rhythm control was associated with a marked reduction in cardiovascular deaths among at-risk stroke patients, said Paulus Kirchhof, MD, director of the department of cardiology at the University Heart and Vascular Center UKE Hamburg, and professor of cardiovascular medicine at the Institute of Cardiovascular Sciences at the University of Birmingham.

When results from the EMPA-REG OUTCOME trial came out, nobody was expecting empagliflozin to have a particularly robust benefit on heart failure and several questions were raised as a result, said Javed Butler, MD, MPH, MBA, chairman for the Department of Medicine at the University of Mississippi.

A recent case report describes a woman with COVID-19 who has had a continuous headache and has not regained her sense of smell since having the disease months ago.

Despite progress from disease-modifying antirheumatic drugs, there is still a far greater long-term risk of undergoing total knee and hip arthroplasties in patients with rheumatoid arthritis.

A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients.

Counties with a smaller proportion of Latinos faced a Latino HIV prevalence rate that was nearly 4 times that of whites, according to a recent study.

Through EVAPORATE, we've been able to show at 18 months that patients taking icosapent ethyl (Vascepa) have less plaque and that there is some atherosclerosis regression, marking mechanisms of benefit for these patients, said Matthew Budoff, MD, professor of medicine at the David Geffen School of Medicine at UCLA and investigator at The Lundquist Institute.

The report explored the use of intravenous lidocaine in a hospital that expanded its use beyond postoperative gastrointestinal surgery.

In addition to high health care and societal costs, spinal muscular atrophy (SMA) is associated with a deterioration in the health-related quality of life of both patients and their caregivers in 3 European countries.

Cardiometabolic comorbidities are a considerable burden in patients with psoriatic arthritis, and patients who had a higher number of cardiovascular (CV) risk factors had greater disease activity, according to a study in Medicina.

A recent report illustrates how advances in allogeneic hematopoietic stem cell transplantation (HSCT) have impacted the outcomes of children with severe acute graft-versus-host-disease.

Children hospitalized with coronavirus disease 2019 (COVID-19) in Wuhan, China presented with a series of eye manifestations, according to a new study.

President Donald Trump promised a coronavirus disease 2019 (COVID-19) vaccine by the end of the year; COVID-19 survivors report anxiety over reinfection; colleges release COVID-19 testing and quarantine data.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Data to be presented at SLEEP 2020 showed Eisai Inc's lemborexant (DAYVIGO) had statistically significant long-term efficacy and safety compared with placebo on sleep maintenance and onset in patients with insomnia disorder, said Margaret Moline, PhD.

This week, the top managed care news included HHS defending a CDC change limiting COVID-19 testing for asymptomatic people; an inside look at the Facing Metastatic Breast Cancer Together campaign; a conversation with Dr Kashyap Patel on his new book.

Most people with systemic lupus erythematosus and inflammatory arthritis, who use medications that make them immunosuppressed, are not necessarily at greater risk of hospitalization from coronavirus disease 2019 (COVID-19), according to 2 studies.

Can muscle mass predict whether patients with chronic obstructive pulmonary disease have a longer hospital stay?

A Boxed Warning on increased risk of leg and foot amputations has been removed from the label of canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.